Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000221034 | SCV000272885 | uncertain significance | not specified | 2015-12-21 | criteria provided, single submitter | clinical testing | The p.Ile3789Thr variant in USH2A has not been previously reported in individual s with hearing loss or Usher syndrome but has been identified in 4/11576 of Lati no chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinsti tute.org; dbSNP rs183979371); however this frequency is not high enough to rule out a pathogenic role. Computational prediction tools and conservation analysis suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical signific ance of the p.Ile3789Thr variant is uncertain. |
Labcorp Genetics |
RCV001047373 | SCV001211325 | uncertain significance | not provided | 2022-09-27 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 3789 of the USH2A protein (p.Ile3789Thr). This variant is present in population databases (rs183979371, gnomAD 0.05%). This missense change has been observed in individual(s) with retinitis pigmentosa (Invitae). ClinVar contains an entry for this variant (Variation ID: 229615). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Blueprint Genetics | RCV001075000 | SCV001240610 | uncertain significance | Retinal dystrophy | 2017-12-22 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001047373 | SCV001875269 | uncertain significance | not provided | 2024-07-26 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
3billion, |
RCV001274942 | SCV003841760 | uncertain significance | Usher syndrome type 2A | 2023-02-23 | criteria provided, single submitter | clinical testing | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.007%). Therefore, this variant is classified as VUS according to the recommendation of ACMG/AMP guideline. |
Genome- |
RCV003454601 | SCV004182111 | uncertain significance | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001274942 | SCV004182112 | uncertain significance | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001047373 | SCV005187234 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Natera, |
RCV001274942 | SCV001459525 | uncertain significance | Usher syndrome type 2A | 2019-11-11 | no assertion criteria provided | clinical testing |